BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 29337092)

  • 41. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
    Blair AB; Groot VP; Gemenetzis G; Wei J; Cameron JL; Weiss MJ; Goggins M; Wolfgang CL; Yu J; He J
    J Am Coll Surg; 2018 Apr; 226(4):630-637.e1. PubMed ID: 29309945
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Diéras V; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Bondarenko I; Campone M; Jakobsen EH; Jalving M; Oprean C; Palácová M; Park YH; Shparyk Y; Yañez E; Khandelwal N; Kundu MG; Dudley M; Ratajczak CK; Maag D; Arun BK
    Lancet Oncol; 2020 Oct; 21(10):1269-1282. PubMed ID: 32861273
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group.
    Andrieu N; Easton DF; Chang-Claude J; Rookus MA; Brohet R; Cardis E; Antoniou AC; Wagner T; Simard J; Evans G; Peock S; Fricker JP; Nogues C; Van't Veer L; Van Leeuwen FE; Goldgar DE
    J Clin Oncol; 2006 Jul; 24(21):3361-6. PubMed ID: 16801631
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.
    Wunderle M; Gass P; Häberle L; Flesch VM; Rauh C; Bani MR; Hack CC; Schrauder MG; Jud SM; Emons J; Erber R; Ekici AB; Hoyer J; Vasileiou G; Kraus C; Reis A; Hartmann A; Lux MP; Beckmann MW; Fasching PA; Hein A
    Breast Cancer Res Treat; 2018 Aug; 171(1):85-94. PubMed ID: 29725888
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
    De Talhouet S; Peron J; Vuilleumier A; Friedlaender A; Viassolo V; Ayme A; Bodmer A; Treilleux I; Lang N; Tille JC; Chappuis PO; Buisson A; Giraud S; Lasset C; Bonadona V; Trédan O; Labidi-Galy SI
    Sci Rep; 2020 Apr; 10(1):7073. PubMed ID: 32341426
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
    Bolton KL; Chenevix-Trench G; Goh C; Sadetzki S; Ramus SJ; Karlan BY; Lambrechts D; Despierre E; Barrowdale D; McGuffog L; Healey S; Easton DF; Sinilnikova O; Benítez J; García MJ; Neuhausen S; Gail MH; Hartge P; Peock S; Frost D; Evans DG; Eeles R; Godwin AK; Daly MB; Kwong A; Ma ES; Lázaro C; Blanco I; Montagna M; D'Andrea E; Nicoletto MO; Johnatty SE; Kjær SK; Jensen A; Høgdall E; Goode EL; Fridley BL; Loud JT; Greene MH; Mai PL; Chetrit A; Lubin F; Hirsh-Yechezkel G; Glendon G; Andrulis IL; Toland AE; Senter L; Gore ME; Gourley C; Michie CO; Song H; Tyrer J; Whittemore AS; McGuire V; Sieh W; Kristoffersson U; Olsson H; Borg Å; Levine DA; Steele L; Beattie MS; Chan S; Nussbaum RL; Moysich KB; Gross J; Cass I; Walsh C; Li AJ; Leuchter R; Gordon O; Garcia-Closas M; Gayther SA; Chanock SJ; Antoniou AC; Pharoah PD; ; ;
    JAMA; 2012 Jan; 307(4):382-90. PubMed ID: 22274685
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
    Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
    JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
    Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
    Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
    Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
    Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
    Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR
    Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
    Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
    J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pregnancy After Breast Cancer in Patients With Germline
    Lambertini M; Ameye L; Hamy AS; Zingarello A; Poorvu PD; Carrasco E; Grinshpun A; Han S; Rousset-Jablonski C; Ferrari A; Paluch-Shimon S; Cortesi L; Senechal C; Miolo G; Pogoda K; Pérez-Fidalgo JA; De Marchis L; Ponzone R; Livraghi L; Estevez-Diz MDP; Villarreal-Garza C; Dieci MV; Clatot F; Berlière M; Graffeo R; Teixeira L; Córdoba O; Sonnenblick A; Luna Pais H; Ignatiadis M; Paesmans M; Partridge AH; Caron O; Saule C; Del Mastro L; Peccatori FA; Azim HA
    J Clin Oncol; 2020 Sep; 38(26):3012-3023. PubMed ID: 32673153
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome.
    Foulkes WD; Chappuis PO; Wong N; Brunet JS; Vesprini D; Rozen F; Yuan ZQ; Pollak MN; Kuperstein G; Narod SA; Bégin LR
    Ann Oncol; 2000 Mar; 11(3):307-13. PubMed ID: 10811497
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis.
    Zhu Y; Wu J; Zhang C; Sun S; Zhang J; Liu W; Huang J; Zhang Z
    Oncotarget; 2016 Oct; 7(43):70113-70127. PubMed ID: 27659521
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.
    Melki R; Melloul M; Aissaoui S; El Harroudi T; Boukhatem N
    BMC Cancer; 2023 Apr; 23(1):339. PubMed ID: 37055759
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
    Hahnen E; Lederer B; Hauke J; Loibl S; Kröber S; Schneeweiss A; Denkert C; Fasching PA; Blohmer JU; Jackisch C; Paepke S; Gerber B; Kümmel S; Schem C; Neidhardt G; Huober J; Rhiem K; Costa S; Altmüller J; Hanusch C; Thiele H; Müller V; Nürnberg P; Karn T; Nekljudova V; Untch M; von Minckwitz G; Schmutzler RK
    JAMA Oncol; 2017 Oct; 3(10):1378-1385. PubMed ID: 28715532
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer?
    Garcia-Etienne CA; Barile M; Gentilini OD; Botteri E; Rotmensz N; Sagona A; Farante G; Galimberti V; Luini A; Veronesi P; Bonanni B
    Ann Surg Oncol; 2009 Dec; 16(12):3380-7. PubMed ID: 19649554
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors.
    Sanford RA; Song J; Gutierrez-Barrera AM; Profato J; Woodson A; Litton JK; Bedrosian I; Albarracin CT; Valero V; Arun B
    Cancer; 2015 Oct; 121(19):3422-7. PubMed ID: 26280679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
    Atchley DP; Albarracin CT; Lopez A; Valero V; Amos CI; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
    J Clin Oncol; 2008 Sep; 26(26):4282-8. PubMed ID: 18779615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.